首页> 外文期刊>Therapeutic advances in medical oncology. >Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma
【24h】

Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma

机译:感应化疗随后是放射疗法与同时化疗治疗不同风险鼻咽癌的鼻咽癌

获取原文
       

摘要

Background: This study aimed to investigate the efficiency and toxicities of concurrent chemoradiotherapy (CCRT) and induction chemotherapy (IC) followed by radiotherapy (RT) in different risk locoregionally advanced nasopharyngeal carcinoma (NPC). Methods: A total of 1814 eligible patients with stage II–IVB disease treated with CCRT or IC plus RT were included. The overall survival (OS), progression-free survival (PFS) and distant metastasis-free survival (DMFS) were calculated using the Kaplan–Meier method, and the differences were compared using the log-rank test. Results: Nomograms were developed to predict OS, PFS and DMFS (C-index: 0.71, 0.70 and 0.71, respectively). Patients were then divided into three different risk groups based on the scores calculated by the nomogram for OS. In the low and intermediate-risk group, no significant survival differences were observed between patients treated with IC plus RT alone and CCRT (5-year OS, 97.3% versus 95.6%, p?=?0.642 and 87.6% versus 89.7%, p?=?0.381, respectively; PFS, 95.9% versus 95.6%, p?=?0.325 and 87.6% versus 89.0%, p?=?0.160, respectively; DMFS, 97.2% versus 94.8%, p?=?0.339 and 87.2% versus 89.3%, p?=?0.628, respectively). However, in the high-risk group, IC plus RT displayed an unfavorable 5-year OS (71.0% versus 77.2%, p?=?0.022) and PFS (69.4.0% versus 75.4%, p?=?0.019) compared with CCRT. A significantly higher incidence of grade 3 and 4 adverse events was documented in patients treated with CCRT than in those treated with IC plus RT in all risk groups ( p?=?0.040). Conclusion: IC followed by RT represents an alternative treatment strategy to CCRT for patients with low and intermediate-risk NPC, but it is not recommended for patients with high-risk NPC.
机译:背景:本研究旨在探讨同时化疗疗法(CCRT)和诱导化疗(IC)的效率和毒性,然后是不同风险的放射治疗(RT),在不同风险上升鼻咽癌(NPC)。方法:包括1814名符合条件的患有CCRT或IC Plus Rt的II-IVB疾病的符合条件的II-IVB疾病患者。使用Kaplan-Meier方法计算总存活(OS),无进展生存期(PFS)和远处转移存活(DMF),使用日志秩检验进行比较差异。结果:开发了拓图以预测OS,PFS和DMFS(C折射率:0.71,0.70和0.71)。然后基于由OS的NOM图计算的分数分为三种不同的风险组。在低和中等风险组中,在IC加上单独治疗的患者和CCRT(5年OS,97.3%对95.6%,P≥1.0.642和87.6%,P <= 0.642和87.6%之间没有显着存活差异.P ?=?0.381分别; PFS,95.9%与95.6%,p?= 0.325和87.6%,p?=?0.160分别; DMF,97.2%对94.8%,p?= 0.339和87.2 %与89.3%,p?=?0.628分别)。然而,在高风险组中,IC加上RT显示出不利的5年次OS(71.0%,p?= 0.022)和PFS(69.4.0%对75.4%,p?= 0.019)比较用ccrt。用CCRT治疗的患者记录了3级和4级不良事件的发病率比在所有风险群体(P?= 0.040)中的IC加RT处理的患者。结论:IC随后RT代表患有低和中性风险NPC患者的替代治疗策略,但不推荐用于高风险NPC的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号